Abstract:BACKGROUND: <AbstractText Label="BACKGROUND">Men often experience deterioration of sexual function after the use of α-blockers and 5-α reductase inhibitors for the treatment of lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia. Thus, an alternative treatment with water vapor thermal therapy (Rezūm System, Boston Scientific, Marlborough, MA, USA) which is an efficacious minimally invasive surgical treatment that preserves sexual function was examined.</AbstractText>AIM: <AbstractText Label="AIM">To compare sexual function over 3 years after continuous daily treatment with pharmaceutical agents in the Medical Therapy of Prostatic Symptoms (MTOPS) study vs a single thermal therapy procedure (Rezūm study) in subjects with matched criteria for LUTS severity and prostate size.</AbstractText>METHODS: <AbstractText Label="METHODS">We used sexual function data from sexually active cohorts in the MTOPS study (1,209) randomized to doxazosin, finasteride, combination drugs and placebo, and sexually active men who received thermal therapy (86). MTOPS study participants completed the Brief Male Sexual Function Inventory; men in the Rezūm trial completed the International Index of Erectile Function and Male Sexual Health Questionnaire.</AbstractText>MAIN OUTCOME MEASURE: <AbstractText Label="MAIN OUTCOME MEASURE">Estimated mean changes from baseline for sexual function variables were compared using a linear mixed repeated measures model with fixed effects for treatment and follow-up visits.</AbstractText>RESULTS: <AbstractText Label="RESULTS">With continued daily drug use, men experienced significant worsening of sexual desire, erectile and ejaculatory function with finasteride and combination drug therapy, and reduced desire and erectile function with doxazosin. Thermal therapy was not associated with significant negative changes in sexual function throughout 3 years after treatment.</AbstractText>CLINICAL IMPLICATIONS: <AbstractText Label="CLINICAL IMPLICATIONS">Water vapor thermal therapy can result in greater LUTS improvements than either doxazosin or finasteride alone, whereas combination drug therapy may equal that of this Rezūm procedure, but all drug therapies did have a significant negative impact on sexual function in contrast to the preservation of libido, erectile, and ejaculatory function after thermal therapy.</AbstractText>STRENGTH & LIMITATIONS: <AbstractText Label="STRENGTH &amp; LIMITATIONS">The report includes high-quality data from 2 large randomized controlled trials in subjects with similar baseline inclusion criteria for LUTS severity and prostate size. It is the first longitudinal assessment of sexual function domains restricted to sexually active men treated with drugs or a single minimally invasive surgical treatment with the Rezūm procedure. A limitation of the study is the use of 2 different, although validated sexual function inventories (Brief Male Sexual Function Inventory and International Index of Erectile Function).</AbstractText>CONCLUSION: <AbstractText Label="CONCLUSION">A single water vapor thermal therapy procedure for targeted prostate tissue ablation for LUTS/ benign prostatic hyperplasia had no deleterious effect on 4 sexual function domains compared with appreciable worsening of sexual function after long-term single or combination drug use. McVary KT, Rogers T, Mahon J, et al. Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia? J Sex Med 2018;15:1728-1738.</AbstractText>

Passive, one-dimensional countercurrent models do not simulate hypertonic urine formation.

Assay of plasminogen (Plg) and alpha 2-antiplasmin (APL) in septic patients.

Rezūm water vapor thermal therapy in patients with benign prostatic hyperplasia: Initial real-world data from Japan

Preservation of Sexual Function 5 Years After Water Vapor Thermal Therapy for Benign Prostatic Hyperplasia

Final 5-Year Outcomes of the Multicenter Randomized Sham-Controlled Trial of a Water Vapor Thermal Therapy for Treatment of Moderate to Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Feasibility assessment of catheter-free water vapor thermal therapy for treatment of benign prostatic hyperplasia

Long-Term Water Vapor Thermal Therapy Outcomes Across a Broad Range of Prostate Volumes

Redesigning care processes using an electronic health record: a system's experience.

Six Novel Minimally Invasive Therapies for Benign Prostatic Hyperplasia

Real-world experience of water vapour therapy (Rezum) in patients with benign prostatic enlargement: a retrospective single-center study

Is Sexual Function Better Preserved After Water Vapor Thermal Therapy or Medical Therapy for Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia?

Growth of herpes simplex virus in epidermal keratinocytes determines cutaneous pathogenicity in mice

Impact of Astroglial Connexins on Modafinil Pharmacological Properties.

Medium-Term Real-World Outcomes of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: Water Vapor Thermal Therapy (Rezum) vs Prostatic Urethral Lift (UroLift) in a High-Volume Urban Academic Center

One hundred cases of Rezum water vapor thermal therapy for benign prostatic hyperplasia: Real‐world data at a single institution in Japan

Transurethral water vapour thermal therapy for benign prostatic hyperplasia under local anaesthesia alone: initial experience in Chinese patients

Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis

Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia

Application of a Chlorophyll Fluorescence Sensor to Detect Chelate-Induced Metal Stress in Zea mays

Minimally invasive treatments for benign prostatic hyperplasia: a Cochrane network meta-analysis

Is water vapor thermal therapy safe and feasible in elderly and frail men? The Italian experience